RIPK3 and neoplasm: It is conceivable that uncoupling necroptotic cell death, the pro-growth inflammation it brings, and CD8+ T-cell cross-priming induction could bring forward the benefits of RIPK3 expression induction in cancer (i.e., antitumor immunity stimulation via cross-priming) and diminish its disadvantages (inflammation, increased tumor growth and necrosis).